Global Myelodysplastic Syndrome Drug Market By Type (Hypomethylating Agents, Immunomodulatory Drugs, and Anti-anemics), By Route Administration (Oral and Parenteral), By End-User (Hospitals, Clinics, and Ambulatory Surgical Centers), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

In 2022, the Global Myelodysplastic Syndrome Drug Market was valued at USD 2.39 Billion. Between 2023 and 2032, and Is Expected To Reach USD 5.79 Billion In 2032 this market is expected to register the highest CAGR of 9.5%.

The drug myelodysplastic syndrome includes a mutation in one or more genes that control how blood cells grow. Anemia, thrombocytopenia, and neutropenia are all possible clinical exposures in this patient population. Anemia, thrombocytopenia, and neutropenia are some clinical exposures that patients may present with. The onset of disease may be triggered by exposure to heavy metals like mercury and lead and chemicals like pesticides, tobacco, and benzene.

Since Vidaza and Dacogen were approved and widely used, there has been a significant increase in demand for hypomethylating agents. Market expansion is anticipated to be boosted in the coming years. Strong commercial opportunities are provided to the market by novel treatments, easy availability, and accessibility in major nations.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• Myelodysplastic Syndromes, also known as Myelodysplastic Disorders (MDS), are bone marrow disorders characterized by abnormal cell production. Hypomethylating agents like Azacitidine and Decitabine have proven very successful at treating MDS.
• In 2022, the global MDS drugs market size was estimated at USD 2.3 Billion; and projected to expand at an average compound annual growth rate of 9.5% until 2032.
• The market for multiple sclerosis drugs (MDS drugs) is driven by rising MDS prevalence, improved diagnosis, no curative therapies available and new drug introduction. Low awareness as well as treatment stoppage due to side effects may inhibit market expansion.
• Celgene/Bristol-Myers Squibb’s Azacitidine holds the largest market share among first-line drugs; other notable medications include Decitabine, Dacogen and Vidaza.
• North America held the largest market share for MDS drugs in 2022; however, Asia Pacific projected to experience the fastest compound annual compound annual compound annual rate over its forecast period.
• This market should be driven by expanding label expansion of existing drugs for new indications as well as by new targeted therapies and immunotherapies such as Rigosertib and SL-401.

Type Analysis

Hypomethylating Agents, Immunomodulatory Drugs, and Anti-anemics are the main segments of Myelodysplastic Syndrome.

The market for medications for myelodysplastic syndrome is divided into immunomodulatory drugs, hypomethylating agents, and anti-anaemics according to their type. Due to increasing therapeutic adoption and a lack of generic competition, immunomodulatory drugs are anticipated to maintain their market dominance.

The medication for low-risk MDS and myelodysplastic syndrome with only Revlimid (lenalidomide) is currently approved. Patients with high-risk myelodysplastic syndrome are treated first time with hypomethylating agents like Vidaza from Celgene and Dacogen from Otsuka. Due to the expiration of the patents on the two mentioned drugs, this market segment has seen a significant decline in market share, resulting in the introduction of various generics.

The anti-anemics drug segment is anticipated to be significantly fueled by Celgene’s luspatercept and Amgen’s Aranesp. Late-stage clinical trials for the medication of myelodysplastic syndrome are looking into both. Recent research has shown that they successfully grow the blood’s RBC count and reduce the need for frequent blood transfusions.

By Route of Administration

The Oral and Parenteral are the Main Routes of Administration in the Myelodysplastic Syndrome Market

Based on the route of administration, the market is divided into oral and parenteral segments. Parenteral products are liquid preparations instead of being swallowing that are injected into human tissues. The word parenteral is used for intestine. Basically, it refers to the administration of medication via intramuscular (IM), intravenous therapy (IV), or subcutaneous (SC) channels. Liquid preparations are distinguished into three classes for injection from other types of pharmaceutical dosage forms: sterility, absence of pyrogens, and particle matt.

Before being administered, single-dose formulations like tablets and capsules are typically ingested whole, chewed, crushed, dissolved, or dispersed in water. One or more active chemicals and excipients that act as diluents, binders, disintegrating agents, or modifiers of the dosage forms and active ingredient behavior in the digestive system are common in oral dosage units. For the treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), the Inqovi tablets were approved by the Food and Drug Administration of the United States.

End-User Analysis

Hospital Segment Dominates the Market Segment for Myelodysplastic Syndrome 

Based on end-users, the market is divided into hospitals, clinics, and other end-users. The myelodysplastic syndrome can lead to leukemia. Medicines and blood transfusions can be used to treat symptoms. The progression of leukemia may be halted or halted by medication or bone marrow transplants, reducing the need for blood transfusions.

As a result, it’s critical to have specialized care, most of which can be found in hospitals. Everyone can use the appointment system easily. The Hospital tries to avoid long lines, delays, and appointment cancellations as much as possible. The staff will inform you of any alterations or disruptions to your therapy.

Key Market Segments

Based on Type

• Hypomethylating Agents
• Immunomodulatory Drugs
• Anti-anemics

 Based on Route Administration

• Oral
• Parenteral

 Based End User

• Hospitals
• Clinics
• Other End-Users

Drivers

Aging Population and Growing Awareness About the Disease are the Main Key Drivers of this Market

The emergence of novel therapeutics is the primary driver of the market. Some of the most important factors expected to drive market expansion are an increase in the geriatric population, an increase in the incidence of niche indications, and improved healthcare services. The market for treatments for myelodysplastic syndrome is expected to grow significantly in the coming years because there are more mutations. This market is being driven primarily by the aging population and growing public awareness of the disease.

Market expansion is also anticipated to be fueled by government initiatives to provide targeted treatment and favorable reimbursement policies. The international foundation for myelodysplastic syndrome is a non-profit health organization that provides patients with psychological support and funds for treatment. Due to this recent advancement, patients with myelodysplastic syndrome, a type of blood cancer, who previously required hospitalization for intravenous therapy now have more treatment options.

Restraints

The high cost of Therapeutics Remains a Hurdle to the Growth of the Market for Myelodysplastic Syndrome.

The major factors hindering the market growth of the myelodysplastic syndrome drug market include the high cost of treatment for myelodysplastic syndrome. Unawareness about the treatment is one of the major factors mitigating the demand for the myelodysplastic syndrome drug market. The complexity and diversity of myelodysplastic syndrome as a disease make it difficult to develop novel treatment options. Convenient treatments can be effective but typically alleviate symptoms.

Stem cell transplantation is currently the only treatment for myelodysplastic syndrome. However, a greater risk is involved, and patients with additional medical complications might not be eligible. The increasing rate of consciousness is projected to hinder the premium pricing strategies of industries in the market.

Opportunity

Growing HealthCare Infrastructure Across Emerging Markets

The myelodysplastic syndrome drug market is also boosted due to growing healthcare industries in several emerging economies such as Brazil, India, South Africa, and China. The rapidly increasing geriatric population, rising per capita incomes, high patient volumes, and spiking awareness among individuals are driving the need to enhance these nations’ healthcare industries.

Therefore, the governments in these economies are increasing their investments to improve healthcare facilities & infrastructure. Owing to the high number of applications of myelodysplastic syndrome drug products in healthcare industries, the rising investment in this industry is expected to offer growth opportunities in the market.

Trends

The Stem Cell Transplant Segment is Expected to Hold Major Market Share in the Myelodysplastic Syndrome Drug Market

Stem cell transplantation is a developing therapy option for people with myelodysplastic syndromes. There are two major kinds of stem cell transplants: allogeneic stem cell transplants and autologous stem cell transplants. After the patient’s bone marrow has been destroyed, they receive blood-forming stem cells from a donator in an allogeneic stem cell transplant. Allogeneic SCTs, on the other hand, can have serious, even fatal, side effects.

However, this is the most common type of transplant for the myelodysplastic syndrome drugs market. As a result, they are typically given to younger, healthier patients. Although lower doses may not remove all bone marrow cells, they are sufficient to allow donor cells to establish themselves and expand within the marrow. This kind of transplant is more tolerable for older patients because of the lower doses and fewer side effects. However, serious adverse effects may still occur. After an autologous stem cell transplant, patients also receive their stem cells.

Regional Analysis

North America is expected to hold Significant Shares in the Market. 

The Myelodysplastic Syndrome (MDS) Drugs Market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World based on regional analysis. North America dominates the global myelodysplastic syndrome treatment market due to the rise in the frequency of myelodysplastic syndrome, early raising of novel medications, high R&D investments in developing novel drugs, and sophisticated healthcare infrastructure.

The number of people detected with myelodysplastic syndrome each year is expected to rise as the United States population ages. Europe is expected to expand significantly over the forecast period due to increased government efforts to identify and treat illnesses. The European LeukemiaNet WP8 created a program to develop and continuously update evidence and consensus-based guidelines to support clinical practice recommendations for standard diagnostic and prognostic procedures and a proper selection of therapeutic medications for adult patients with primary myelodysplastic syndrome.

These recommendations were to be made for patients who had myelodysplastic syndrome. Major players and charities are present in the region, with the goal of launching new programs and awareness campaigns to educate the public and assist medical professionals in treating myelodysplastic syndrome.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

Emerging key players are focused on various strategic policies to develop their respective businesses in foreign markets. Several myelodysplastic syndrome drug market companies are concentrating on expanding their existing operations and R&D facilities.

Furthermore, businesses in the myelodysplastic syndrome drugs market are developing new products and portfolio expansion strategies through investments, mergers, and acquisitions. In addition, several key players are now focusing on different marketing strategies, such as spreading awareness about natural ingredients, which is boosting the target products’ growth.

Market Key Players

With the presence of many local and regional players, the global myelodysplastic syndrome drug market is fragmented. Market players are subject to intense competition from top market players, particularly those with strong brand recognition and high distribution networks. Companies have gained various expansion strategies, such as partnerships and product launches, to stay on top of the market.

• Celgene Corporation
• Otsuka Pharmaceutical Co. Ltd
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Limited
• Takeda Pharmaceutical Company Ltd
• Mylan N.V.
• Cipla Pharmaceutical Limited
• Other Key Players

Recent Developments

In 2022: The United State Food and Drug Administration granted an orphan drug designated to syros pharmaceuticals oral therapy, tamibarotene, to treat Myelodysplastic syndrome.

In 2022: Accord Healthcare Announced the UK launch of generic lenalidomide available for treating adult patients with multiple myeloma, Myelodysplastic Syndrome, and mantle cell lymphoma.

Report Scope